Tisotumab vedotin extravasation injury in a patient with recurrent cervical cancer

被引：0
|
作者：
Son, Ji [1 ]
Cain, Katherine E. [2 ]
Marten, Claire A. [2 ]
Dwyer, Kaitlin W. [1 ]
Sims, Travis T. [1 ]
Taylor, Jolyn S. [1 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Dept Gynecol Oncol & Reprod Med, Houston, TX 77030 USA
[2] Univ Texas MD Anderson Canc Ctr, Dept Pharm Clin Programs, Houston, TX USA
来源：
GYNECOLOGIC ONCOLOGY REPORTS | 2024年 / 56卷
关键词：
SQUAMOUS-CELL-CARCINOMA; PREVIOUSLY TREATED RECURRENT; PHASE-II; TISSUE FACTOR; PERSISTENT; TRIAL;
D O I：
10.1016/j.gore.2024.101525
中图分类号：
R71 [妇产科学];
学科分类号：
100211 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Tisotumab vedotin effective in recurrent cervical cancer
    Sidaway, Peter
    NATURE REVIEWS CLINICAL ONCOLOGY, 2024, 21 (10) : 703 - 703
  • [2] Tisotumab vedotin in recurrent or metastatic cervical cancer
    Bogani, Giorgio
    Coleman, Robert L.
    Vergote, Ignace
    Raspagliesi, Francesco
    Lorusso, Domenica
    Monk, Bradley J.
    CURRENT PROBLEMS IN CANCER, 2023, 47 (03)
  • [3] Tisotumab Vedotin in Previously Treated Recurrent or Metastatic Cervical Cancer
    Hong, David S.
    Concin, Nicole
    Vergote, Ignace
    de Bono, Johann S.
    Slomovitz, Brian M.
    Drew, Yvette
    Arkenau, Hendrik-Tobias
    Machiels, Jean-Pascal
    Spicer, James F.
    Jones, Robert
    Forster, Martin D.
    Cornez, Nathalie
    Gennigens, Christine
    Johnson, Melissa L.
    Thistlethwaite, Fiona C.
    Rangwala, Reshma A.
    Ghatta, Srinivas
    Windfeld, Kristian
    Harris, Jeffrey R.
    Lassen, Ulrik Niels
    Coleman, Robert L.
    CLINICAL CANCER RESEARCH, 2020, 26 (06) : 1220 - 1228
  • [4] Tisotumab Vedotin-tftv Approved for Recurrent or Metastatic Cervical Cancer
    Schuyler, Devon
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2021, 19 (10) : 649 - 649
  • [5] A Review of Tisotumab Vedotin-tftv in Recurrent or Metastatic Cervical Cancer
    Heitz, Nathan
    Greer, Samuel C.
    Halford, Zachery
    ANNALS OF PHARMACOTHERAPY, 2023, 57 (05) : 585 - 596
  • [6] Study Sees Encouraging Responses With Tisotumab Vedotin in Recurrent/Metastatic Cervical Cancer
    不详
    ONCOLOGY-NEW YORK, 2020, 34 (11): : 487 - 487
  • [7] Tisotumab Vedotin as Second- or Third-Line Therapy for Recurrent Cervical Cancer
    Vergote, Ignace
    Gonzalez-Martin, Antonio
    Fujiwara, Keiichi
    Kalbacher, Elsa
    Bagameri, Andrea
    Ghamande, Sharad
    Lee, Jung-Yun
    Banerjee, Susana
    Maluf, Fernando Cotait
    Lorusso, Domenica
    Yonemori, Kan
    Van Nieuwenhuysen, Els
    Manso, Luis
    Woelber, Linn
    Westermann, Anneke
    Covens, Allan
    Hasegawa, Kosei
    Kim, Byoung-Gie
    Raimondo, Miriam
    Bjurberg, Maria
    Cruz, Felipe Melo
    Angelergues, Antoine
    Cibula, David
    Barraclough, Lisa
    Oaknin, Ana
    Gennigens, Christine
    Nicacio, Leo
    Teng, Melinda Siew Leng
    Whalley, Elizabeth
    Soumaoro, Ibrahima
    Slomovitz, Brian M.
    NEW ENGLAND JOURNAL OF MEDICINE, 2024, 391 (01): : 44 - 55
  • [8] Antibody drug conjugates in recurrent or metastatic cervical cancer: a focus on tisotumab vedotin state of art
    Camarda, Floriana
    Paderno, Mariachiara
    Cannizzaro, Maria Chiara
    Nero, Camilla
    Sabatucci, Ilaria
    Fuca, Giovanni
    Musacchio, Lucia
    Salutari, Vanda
    Scambia, Giovanni
    Lorusso, Domenica
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2024, 16
  • [9] Tisotumab vedotin for the treatment of cervical carcinoma
    Song, Xin
    Li, Ruyi
    Wang, Hongwei
    Song, Peng
    Guo, Wenjing
    Chen, Zhe-Sheng
    DRUGS OF TODAY, 2022, 58 (05) : 213 - 222
  • [10] Expert Commentary on the Product Profile of Tisotumab Vedotin in Cervical Cancer
    Bucher-Bailey, Laura
    ONCOLOGY-NEW YORK, 2024, 38 (09):
12345